In addition, recent studies have shown that PI3K inhibitors (i.e., alpelisib) have significant clinical activity against PIK3CA-mutated luminal breast cancers, including ET-resistant tumor cells [80]. This evidence concerns the gene PIK3CA and breast carcinoma.